Evidence map›Paper›PMID 26862360›Full record

ArticleThe open ophthalmology journal2015

Corneal Infection Therapy with Topical Bacteriophage Administration.

Ali Fadlallah, Elias Chelala, Jean-Marc Legeais

Open access · diamondAbstract read
In one paragraph

Article in The open ophthalmology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Microbial keratitis in the age of resistance: unlocking the therapeutic potential of phage therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  6. The Ability of Bacteriophages to Reduce Biofilms Produced byAntibiotics (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. A Century of Clinical Use of Phages: A Literature Review.Antibiotics (Basel, Switzerland) · 2023
    Review
  13. Review
  14. Frontiers in cell and developmental biology · 2023
    Review
  15. Frontiers in cellular and infection microbiology · 2023
    Review
  16. Review
  17. Article
  18. Considerations for the Use of Phage Therapy in Clinical Practice.Antimicrobial agents and chemotherapy · 2022
    Review
  19. Article
  20. Bacteriophage Therapy forFrontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Ali FadlallahPierre et Marie Curie University, Sorbonne Universities, Paris, France; Hôtel Dieu de Paris Hospital, Paris, France.
Elias ChelalaSaint-Joseph university, Faculty of Medicine, Beirut, Lebanon.
Jean-Marc LegeaisParis Descartes University, Paris, France; Hôtel Dieu de Paris Hospital, Paris, France.
Saint Joseph University · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus is a major pathogen in bacterial keratitis, a vision-threatening disease. Although the incidence of S. aureus keratitis varies worldwide, the increasing trend of resistance to certain antibiotics makes this condition an important, global, healthcare concern. We report the case of a 65-year-old woman with nosocomial left-eye corneal abscess and interstitial keratitis.The patient then undergo topical Phage therapy with successful results.

Indexed as

Interstitial Keratitisphage therapy.VRSA

Identifiers

PMID26862360
PMCPMC4740968
OpenAlexW2096709892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.